On April 6, 2026, Ensysce Biosciences, Inc. completed a $2 million equity offering, selling 2,000 shares of Series B preferred stock and up to 4,363,636 shares of common stock upon conversion, along with warrants for 8,727,273 shares at a $0.55 exercise price.